VIRxSYS has developed an extensive portfolio of intellectual property which is protected by a combination of patents, trade secrets, and trademark law. Below is a summary of the Company’s parent patents in the United States. VIRxSYS also has many foreign counterparts in countries around the world.
Patent/Ser No.
Issue / Publication Date
Title
US 5,885,806
March 23, 1999
Methods to Prepare Conditionally Replicating Viral Vectors
US 6,114,141
September 5, 2000
Method to Express Genes from Viral Vectors
09/667,893
Filed September 22, 2000
Conditionally Replicating Vectors and Methods for Their Production and Use
US 6,168,953
January 2, 2001
Genetic Antiviral Agents and Methods for Their Use
US 6,207,426
March 27, 2001
Conditionally Replicating Viral Vectors and their Use
US 6,410,257
June 25, 2002
Method to Express Genes from Viral Vectors
US 6,498,033
December 24, 2002
Lentiviral Vectors
US 6,627,442
September 30, 2003
Methods for a Stable Transduction of Cells with HIV-Derived Viral Vectors
US 20040203017
October 14, 2004
High-Throughput Methods for Identifying Gene Function using Lentiviral Vectors
US 6,835,568
December 28, 2004
Regulated Nucleic Acid Expression System
US 20050123514
June 9, 2005
Increased Transduction Using ABC Transporter Substrates and/or Inhibitors
US 20060003452
June 30, 2005
Vector Packaging Cell Line
US 20050196381
September 8, 2005
Two-vector Complementary Systems for Generating Immune Responses
11/424,673
Filed October 20, 2005
Antibody Complexes
US 20050257277
November 17, 2005
Regulation of Transcription with a Cis-acting Ribozyme
10/587,437
Filed May 22, 2006
Transduction of Primary Cells
"VIRxSYS has a powerful portfolio of technology in lentiviral vectors and cell process manufacturing which we protect with a combination of patents and trade secret laws."
Gary McGarrity, VIRxSYS EVP Scientific and Clinical Affairs